The U.S. National Institutes of Health did not recognize consensus neuropathological criteria for the post-mortem diagnosis of CTE until 2015, when an international team of neuropathologists developed the National Institute of Neurological Disorder and Stroke/National Institute of Biomedical Imaging and Bioengineering (NINDS/NIBIB) criteria, which defined the pathognomonic lesion of CTE as “an accumulation of abnormal hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels at the depths of cortical sulci and in an irregular pattern” (31). Here, MAPT is linked to stroke disorder.